Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC

2020 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC.

Osimertinib, a third-generation central nervous system (CNS)-active EGFR-targeting tyrosine kinase inhibitor, is approved for the first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21L858R mutations as detected by a US Food and Drug Administration–approved test.1,2

The double-blind, randomized phase 3 ADAURA trial evaluated the efficacy and safety of osimertinib compared with placebo in patients with completely resected, stage IB to IIIA, EGFR mutation–positive NSCLC, after adjuvant chemotherapy.1 Following independent data monitoring committee recommendations, the trial was unblinded early due to efficacy. The researchers reported interim results from the trial, which included 682 patients who were randomized to osimertinib 80 mg once daily (N = 339) or placebo (N = 343) for 3 years. The primary end point was investigator-assessed disease-free survival (DFS) among patients with stage II to IIIA disease (N = 470). Secondary end points included DFS in the overall population of patients with stage IB to IIIA disease, overall survival (OS), and safety.1

At 24 months in patients with stage II to IIIA disease, 90% (95% confidence interval [CI], 84%-93%) of those in the osimertinib group and 44% (95% CI, 37%-51%) of those in the placebo group were alive and disease-free (hazard ratio [HR], 0.17; P <.001).1 Median DFS was not reached (95% CI, 38.8 months-not calculable [NC]) in the osimertinib group compared with 19.6 months (95% CI, 16.6-24.5 months) in the placebo group. At 24 months in the overall population, 89% (95% CI, 85%-92%) of those in the osimertinib group and 52% (95% CI, 46%-58%) of those in the placebo group were alive and disease-free at 24 months (HR, 0.20; P <.001). Median DFS was not reached (95% CI, NC-NC) in the osimertinib group compared with 27.5 months (95% CI, 22.0-35.0 months) in the placebo group. A clinically meaningful increase in CNS DFS was observed in the osimertinib group versus the placebo group (98% [95% CI, 95-99] vs 85% [95% CI, 80-89]; HR, 0.18; 95% CI, 0.10-0.33). OS data were immature. At the data cutoff, 9 deaths occurred in the osimertinib group and 20 in the placebo group.1

The most common adverse events (AEs) of any grade with osimertinib were diarrhea (46% vs 20% in the placebo group), paronychia (25% vs 1%), and dry skin (23% vs 6%).1 Grade ≥3 AEs occurred in 20% of patients in the osimertinib group and 13% of those in the placebo group. Serious AEs were reported in 16% of patients in the osimertinib group compared with 12% of those in the placebo group. AEs led to treatment discontinuation in 11% of patients in the osimertinib group and 3% of those in the placebo group. No fatal AEs were reported with osimertinib; 1 fatal AE (pulmonary embolism) occurred with placebo.1

The researchers concluded that osimertinib is an effective new treatment in the adjuvant setting for patients with stage IB to IIIA EGFR mutation–positive NSCLC.1

References
1. Wu YL, et al. N Engl J Med. 2020;383:1711-1723.
2. US Food and Drug Administration. FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations. Accessed December 17, 2020.

Related Items
NSCLC Year in Review Introduction
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Lower Dose of Afatinib Shows Promising Clinical Efficacy in Patients with NSCLC and EGFR Mutation
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Bevacizumab + Osimertinib Did Not Increase Progression-Free Survival versus Osimertinib Alone in Patients with Advanced Adenocarcinoma and EGFR T790M Mutations
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Patritumab Deruxtecan Shows Promise in Treating Patients with EGFR-Mutated NSCLC
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Inhibition of VEGFR and EGFR with Apatinib + Gefitinib as First-Line Therapy Increased Progression-Free Survival
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
ALEX Trial: Alectinib versus Crizotinib in Treatment-Naïve Advanced ALK-Positive NSCLC
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
FLAURA Trial: Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Savolitinib Shows Potential for Patients with NSCLC and MET Exon 14 Skipping Mutations
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Poziotinib Shows Promise for Treating Patients with NSCLC and EGFR or HER2 Exon 20 Insertion Mutations
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
RELAY Results: Patients with Exon 21 L858R or Exon 19 Deletion Mutations of EGFR Benefit from Ramucirumab + Erlotinib
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: January 29, 2021